Sutro Biopharma, Inc.(STRO)

$21.31—Stale · unknown old

Chart

Sutro Biopharma, Inc.(STRO)

NASDAQ • Last print unknown ago

$21.31—Stale · unknown old

Chart Studio

STRO(STRO)

STRO

Overview Fair Value Stream Notebook Intel Chart History Fundamentals TTM Earnings Analysts News Financials Insiders Institl.DCF Peers

Q4 2026 EPS Estimate

$-1.66

Nov 5, 2026

Revenue Estimate

$14M

Analyst Sentiment

Wall St. Consensus

Buy

20 analysts·High coverage

Score

18 Buy (90%)1 Hold (5%)1 Sell (5%)

Rating Breakdown

Strong Buy

00%

Buy

1890%

Hold

15%

Sell

15%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$43.00

+101.8%

Consensus

$50.00

+134.6%

Bull

$60.00

+181.6%

12-Month Target Range20 analysts

$43.00$50.00$60.00

Current $21.31Consensus

Current Price

$21.31

Upside to Consensus

$28.69

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev-31.40%

EPS—

FY2028

Rev+11.52%

EPS—

FY2029

Rev+0.09%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$50M	$34M	$38M	$38M	$75M
Low	$38M	$2M	$20M	$20M	$39M
High	$58M	$70M	$79M	$79M	$154M
EBITDA Avg	$-44M	$-30M	$-34M	$-34M	$-66M
Low	$-51M	$-62M	$-70M	$-70M	$-137M
High	$-34M	$-2M	$-18M	$-18M	$-34M
EBIT Avg	$-45M	$-31M	$-34M	$-34M	$-67M
Low	$-52M	$-63M	$-71M	$-71M	$-139M
High	$-34M	$-2M	$-18M	$-18M	$-35M
Net Income Avg	$-68M	$-57M	$-51M	$-48M	$-44M
Low	$-84M	$-81M	$-81M	$-115M	$-105M
High	$-52M	$-34M	$-20M	$-18M	$-17M
EPS Avg	$-8.03	$-6.39	$-6.19	$-5.66	$-5.19
Low	$-9.85	$-9.55	$-9.52	$-13.51	$-12.39
High	$-6.10	$-3.96	$-2.36	$-2.13	$-1.95
Analysts (Rev / EPS)	9 / 7	10 / 8	9 / 9	4 / 3	4 / 3

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027
Revenue Avg	$14M	$14M	$9M	$8M	$8M	$9M
Low	$5M	$4M	$1M	$1M	$1M	$1M
High	$21M	$21M	$22M	$21M	$21M	$22M
EBITDA Avg	$-12M	$-12M	$-8M	$-7M	$-7M	$-8M
Low	$-18M	$-18M	$-19M	$-19M	$-19M	$-19M
High	$-5M	$-3M	$-1M	$-1M	$-1M	$-1M
EBIT Avg	$-12M	$-12M	$-8M	$-7M	$-7M	$-8M
Low	$-18M	$-19M	$-19M	$-19M	$-19M	$-20M
High	$-5M	$-3M	$-1M	$-1M	$-1M	$-1M
Net Income Avg	$-28M	$-26M	$-33M	$-29M	$-29M	$-26M
Low	$-35M	$-35M	$-100M	$-87M	$-86M	$-76M
High	$-21M	$-15M	$3M	$3M	$3M	$2M
EPS Avg	$-1.66	$-1.55	$-2.02	$-1.77	$-1.74	$-1.55
Low	$-2.11	$-2.11	$-6.02	$-5.28	$-5.20	$-4.61
High	$-1.24	$-0.93	$0.19	$0.17	$0.16	$0.15
Analysts (Rev / EPS)	8 / 3	8 / 4	4 / 1	5 / 1	4 / 1	5 / 1

Earnings Surprises

Recent Analyst Actions

Aug 7, 2026Stifel Nicolaus

Sutro Biopharma initiated with a Buy at Stifel

Target:$48.00

+98.8%from $24.15

Jun 11, 2026Truist Financial

Sutro Biopharma assumed with a Buy at Truist

Target:$50.00

+91.6%from $26.09

May 28, 2026Barclays

Barclays Starts Sutro Biopharma (STRO) at Overweight

Target:$56.00

+88.6%from $29.69

May 15, 2026Wedbush

Sutro Biopharma upgraded to Outperform from Neutral at Wedbush

Target:$60.00

+56.2%from $38.42

May 15, 2026H.C. Wainwright

Sutro Biopharma price target raised to $50 from $28 at H.C. Wainwright

Target:$50.00

+30.1%from $38.42

May 15, 2026Leerink Partners

Sutro Biopharma price target raised to $43 from $38 at Leerink

Target:$43.00

+11.9%from $38.42

Apr 30, 2026Mizuho Securities

Sutro Biopharma initiated with an Outperform at Mizuho

Target:$50.00

+41.3%from $35.39

Mar 14, 2025Piper Sandler

Sutro Biopharma downgraded to Neutral from Overweight at Piper Sandler

Target:$2.00

-75.3%from $8.10

Oct 11, 2024Bank of America Securities

BofA Securities Reiterates Buy Rating on Sutro Biopharma (STRO)

Target:$12.00

-66.7%from $36.05

Oct 11, 2024H.C. Wainwright

H.C. Wainwright Reiterates Buy Rating on Sutro Biopharma (STRO)

Target:$12.00

-66.8%from $36.10

Aug 16, 2024Truist Financial

Sutro Biopharma (STRO) PT Lowered to $15 at Truist Securities

Target:$15.00

-64.4%from $42.10

May 14, 2024Deutsche Bank

Sutro Biopharma (STRO) PT Lowered to $10 at Deutsche Bank

Target:$10.00

-77.0%from $43.40

May 14, 2024Wedbush

Wedbush Reiterates Outperform Rating on Sutro Biopharma (STRO)

Target:$8.00

-81.1%from $42.30

Apr 3, 2024Oppenheimer

Oppenheimer Reiterates Outperform Rating on Sutro Biopharma (STRO)

Target:$10.00

-80.4%from $50.90

Apr 3, 2024Piper Sandler

Sutro Biopharma (STRO) PT Lowered to $11 at Piper Sandler

Target:$11.00

-78.4%from $50.90

Apr 2, 2024Truist Financial

Sutro Biopharma (STRO) PT Lowered to $18 at Truist Securities

Target:$18.00

-64.6%from $50.90

Jan 13, 2023Truist Financial

Truist Securities Maintains Buy on Sutro Biopharma, Raises Price Target to $25

Target:$25.00

-69.3%from $81.35

Jan 10, 2023Piper Sandler

Piper Sandler Maintains Overweight on Sutro Biopharma, Raises Price Target to $18

Target:$18.00

-78.3%from $82.90

Jun 28, 2022Piper Sandler

Sutro Biopharma price target raised to $16 from $14 at Piper Sandler

Target:$16.00

-68.3%from $50.50

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance